Evaluation and Treatment of Patients with Major Depressive Disorder: Are We Considering All the Options?

Megan Maroney, PharmD
Published Online: Wednesday, August 22, 2012
This activity is supported by an educational grant from Mylan Specialty, LP.
 
Evaluation and Treatment of Patients with Major Depressive Disorder: Are We Considering All the Options?
 
Megan Maroney, PharmD

Clinical Assistant Professor
Ernest Mario School of Pharmacy
Rutgers University
Piscataway, New Jersey
Clinical Psychiatric Pharmacist
Monmouth Medical Center
Long Branch, New Jersey

 

 
Megan Maroney, PharmD, has no financial relationships with commercial interests to disclose related to this activity.
 
Pharmacy Times Office of Continuing Professional Education Planning Staff
 
Judy V. Lum, MPA, Ann C. Lichti, CCMEP, and Elena Beyzarov, PharmD, have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.
 
Pharmacy Times Editorial Staff
 
Jennifer Whartenby and David Allikas have no relevant affiliations or financial relationships with commercial interests to disclose related to this activity.
 
The peer reviewer of this activity has no relevant financial relationships with commercial interests to disclose related to this activity.
 

 
Educational Objectives
 
Upon completion of this educational activity, participants should be able to:
  1. Review the pathophysiology and epidemiology of major depressive disorder (MDD), atypical depression, and treatment-resistant depression.
  2. Address challenges of treating depression, including safety concerns (eg, adverse effects, drug–food interactions), noncompliance, relapse, and inadequate response to antidepressant therapy.
  3. Discuss current and emerging antidepressant treatments, including strategies used for typical and treatment-resistant depression.
  4. Formulate counseling strategies to improve patient outcomes in depression.
Target audience: Pharmacists
Type of activity: Knowledge
Release date: August 10, 2012
Expiration date: August 10, 2014
Estimated time to complete activity: 2 hours
Fee: This lesson is free online
 
Click here to view this activity.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues
$auto_registration$